For the year ending 2025-12-31, CTSO made $37,063,000 in revenue. -$8,198,000 in net income. Net profit margin of -22.12%.
| Income Statement | 2025-12-31 | 2024-12-31 | ||
|---|---|---|---|---|
| Revenue, net | 37,063,000 | 35,594,520 | ||
| Cost of goods sold | 10,572,000 | 10,468,529 | ||
| Gross profit | 26,491,000 | 25,125,991 | ||
| Research and development, net of grant income | 5,085,000 | 6,916,181 | ||
| Selling, general and administrative | 35,645,000 | 34,995,749 | ||
| Restructuring | 510,000 | - | ||
| Total operating expenses | 41,240,000 | 41,911,930 | ||
| Loss from operations | -14,749,000 | -16,785,939 | ||
| Interest expense, net | -2,612,000 | -1,399,092 | ||
| Gain (loss) on foreign currency transactions | 9,321,000 | -4,224,721 | ||
| Miscellaneous income (expense) | - | -30 | ||
| Loss on abandoned patents | 559,000 | - | ||
| Total other income (expense), net | 6,150,000 | -5,623,843 | ||
| Loss before benefit from income taxes | -8,599,000 | -22,409,782 | ||
| Benefit from income taxes | -401,000 | -1,690,825 | ||
| Net loss | -8,198,000 | -20,718,957 | ||
| Basic EPS | -0.13 | -0.38 | ||
| Diluted EPS | -0.13 | -0.38 | ||
| Basic Average Shares | 62,231,771 | 54,434,609 | ||
| Diluted Average Shares | 62,231,771 | 54,434,609 | ||
Cytosorbents Corp (CTSO)
Cytosorbents Corp (CTSO)